Statins in endothelial signaling and activation

Antioxidants and Redox Signaling

Volumn 11, Issue 4, 2009, Pages 811-821

  Jacobson, Jeffrey R ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC 6026 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAC1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANTIOXIDANT ACTIVITY; CELL ACTIVATION; CYTOSKELETON; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULARIZATION; ANIMAL; DRUG EFFECTS; ENDOTHELIUM; METABOLISM;

ANIMALIA;

ANIMALS; CYTOSKELETON; ENDOTHELIUM; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; SIGNAL TRANSDUCTION;

EID: 60749131372     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2008.2284     Document Type: Review

References (90)

1. Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Lancet 344: 1383-1389, 1994.
2. Multicentre Anti-Atheroma Study (MAAS). Effect of simvastatin on coronary atheroma: the Lancet 344: 633-638, 1994.
3. Adhikari N, Burns KE, and Meade MO. Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: systematic review and meta-analysis. Treat Respir Med 3: 307-328, 2004.
4. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, and Iida M. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109: 227-233, 2004.
5. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, and Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110: 880-885, 2004.
6. Alvarez de Sotomayor M, Perez-Guerrero C, Herrera MD, and Marhuenda E. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 17: 769-776, 1999.
7. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, and Brandes RP. Direct interaction of the novel nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 279: 45935-45941, 2004.
8. Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, and Hemmings BA. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (Rac-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A 93: 5699-5704, 1996.
9. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, and Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122, 2007.
10. Bogatcheva NV, Birukova A, Borbiev T, Kolosova I, Liu F, Garcia JG, and Verin AD. Caldesmon is a cytoskeletal target for PKC in endothelium. J Cell Biochem 99: 1593-1605, 2006.
11. Bourcier T and Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20: 556-562, 2000.
12. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, and Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89: 866-873, 2001.
13. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, and Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505-1515, 2004.
14. Chen W, Pendyala S, Natarajan V, Garcia JGN, and Jacobson JR. Endothelial barrier regulation by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol 295: L575-L583, 2008.
15. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280: 34202-34209, 2005.
16. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605, 1999.
17. Di-Poi N, Faure J, Grizot S, Molnar G, Pick E, and Dagher MC. Mechanism of NADPH oxidase activation by the Rac/Rho-GDI complex. Biochemistry 40: 10014-10022, 2001.
18. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, and Coxon FP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21: 684-694, 2006.
19. Durant R, Klouche K, Delbosc S, Morena M, Amigues L, Beraud JJ, Canaud B, and Cristol JP. Superoxide anion overproduction in sepsis: effects of vitamin E and simvastatin. Shock 22: 34-39, 2004.
20. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, and Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95: 8880-8885, 1998.
21. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 9: 946-955, 1995.
22. Etienne-Manneville S and Hall A. Rho GTPases in cell biology. Nature 420: 629-635, 2002.
23. Eto M, Kozai T, Cosentino F, Joch H, and Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105: 1756-1759, 2002.
24. Eto M, Rathgeb L, Cosentino F, Kozai T, and Luscher TF. Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. J Cardiovasc Pharmacol 47: 663-667, 2006.
25. Falagas ME, Makris GC, Matthaiou DK, and Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 61: 774-785, 2008.
26. Fay WP, Garg N, and Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 27: 1231-1237, 2007.
27. Feron O, Dessy C, Desager JP, and Balligand JL. Hydroxymethylglutaryl- coenzyme a reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103: 113-118, 2001.
28. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, and Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280: 17286-17293, 2005.
29. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, and Busse R. Phosphorylation of thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88: E68-E75, 2001.
30. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, and French WJ. Effect of statin use within the first 24 h of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96: 611-616, 2005.
31. Forstermann U, Mulsch A, Bohme E, and Busse R. Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Circ Res 58: 531-538, 1986.
32. Fujii T, Onimaru M, Yonemitsu Y, Kuwano H, and Sueishi K. Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression. Am J Physiol Heart Circ Physiol 294: H2785-H2791, 2008.
33. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, and Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601, 1999.
34. Gao XP, Standiford TJ, Rahman A, Newstead M, Holland SM, Dinauer MC, Liu QH, and Malik AB. Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by gram-negative sepsis: Studies in p47phox-/- and gp91phox-/- mice. J Immunol 168: 3974-3982, 2002.
35. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, and English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108: 689-701, 2001.
36. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, and Sessa WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392: 821-824, 1998.
37. Giancotti FG and Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 19: 173-206, 2003.
38. Goldstein JL and Brown MS. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
39. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, and Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87: 26-32, 2000.
40. Heeba G, Hassan MK, Khalifa M, and Malinski T. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc Pharmacol 50: 391-398, 2007.
41. Hogervorst F, Kuikman I, von dem Borne AE, and Sonnenberg A. Cloning and sequence analysis of beta-4 cDNA: an integrin subunit that contains a unique 118 kd cytoplasmic domain. EMBO J 9: 765-770, 1990.
42. Ignarro LJ, Harbison RG, Wood KS, and Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 237: 893-900, 1986.
43. Jacobson JR, Dudek SM, Birukov KG, Ye SQ, Grigoryev DN, Girgis RE, and Garcia JG. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 30: 662-670, 2004.
44. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, and Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288: L1026-L1032, 2005.
45. Jacobson JR, Dudek SM, Singleton PA, Kolosova IA, Verin AD, and Garcia JG. Endothelial cell barrier enhancement by ATP is mediated by the small GTPase Rac and cortactin. Am J Physiol Lung Cell Mol Physiol 291: L289-L295, 2006.
46. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, and Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 271: H1626-H1634, 1996.
47. Kosmidou I, Moore JP, Weber M, and Searles CD. Statin treatment and 3′polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol 27: 2642-2649, 2007.
48. Kruger P, Fitzsimmons K, Cook D, Jones M, and Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intens Care Med 32: 75-79, 2006.
49. Kunieda Y, Nakagawa K, Nishimura H, Kato H, Ukimura N, Yano S, Kawano H, Kimura S, Nakagawa M, and Tsuji H. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res 110: 227-234, 2003.
50. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HNG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
51. Laufs U, La Fata V, Plutzky J, and Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998.
52. Laufs U and Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
53. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, and Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of Rho GTPase gene transcription. Circulation 102: 3104-3110, 2000.
54. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, and Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88: 1306-1307, 2001.
55. Le Cras TD, Xue C, Rengasamy A, and Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol 270: L164-L170, 1996.
56. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, and Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100: 178-184, 1999.
57. Li JM and Shah AM. Differential NADPH- versus NADH-dependent superoxide production by phagocyte-type endothelial cell NADPH oxidase. Cardiovasc Res 52: 477-486, 2001.
58. Liappis AP, Kan VL, Rochester CG, and Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33: 1352-1357, 2001.
59. Lin SJ, Chen YH, Lin FY, Hsieh LY, Wang SH, Lin CY, Wang YC, Ku HH, Chen JW, and Chen YL. Pravastatin induces thrombomodulin expression in TNFalpha-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity. J Cell Biochem 101: 642-653, 2007.
60. Liu F, Schaphorst KL, Verin AD, Jacobs K, Birukova A, Day RM, Bogatcheva N, Bottaro DP, and Garcia JG. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB J 16: 950-962, 2002.
61. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18: 69-82, 2006.
62. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, and Miyamori I. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 23: 512-517, 2003.
63. Morawietz H, Erbs S, Holtz J, Schubert A, Krekler M, Goettsch W, Kuss O, Adams V, Lenk K, Mohr FW, Schuler G, and Hambrecht R. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: The EPAS trial. Circulation 114: I296-301, 2006.
64. Mortensen EM, Restrepo MI, Anzueto A, and Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 6: 82, 2005.
65. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, and Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100: 2131-2134, 1999.
66. Ohara Y, Peterson TE, and Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551, 1993.
67. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, and Galper JB. 3-Hydroxy-3- methylglutaryl coenzyme a reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143-150, 2002.
68. Perez-Guerrero C, Alvarez de Sotomayor M, Jimenez L, Herrera MD, and Marhuenda E. Effects of simvastatin on endothelial function after chronic inhibition of nitric oxide synthase by L-NAME. J Cardiovasc Pharmacol 42: 204-210, 2003.
69. Ramasamy S, Parthasarathy S, and Harrison DG. Regulation of endothelial nitric oxide synthase gene expression by oxidized linoleic acid. J Lipid Res 39: 268-276, 1998.
70. Sato K, Kadiiska MB, Ghio AJ, Corbett J, Fann YC, Holland SM, Thurman RG, and Mason RP. In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS. FASEB J 16: 1713-1720, 2002.
71. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)h oxidase activity: upstream mediators. Circ Res 91: 406-413, 2002.
72. Shepherd J. The West of Scotland Coronary Prevention Study: A trial of cholesterol reduction in Scottish men. Am J Cardiol 76: 113C-117C, 1995.
73. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, and Hauer-Jensen M. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14: 575-585, 2003.
74. Skaletz-Rorowski A, Lutchman M, Kureishi Y, Lefer DJ, Faust JR, and Walsh K. HMG- CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc Res 57: 253-264, 2003.
75. Stasek JE Jr, Patterson CE, and Garcia JG. Protein kinase c phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J Cell Physiol 153: 62-75, 1992.
76. Tamura M, Kai T, Tsunawaki S, Lambeth JD, and Kameda K. Direct interaction of actin with p47(phox) of neutrophil NADPH oxidase. Biochem Biophys Res Commun 276: 1186-1190, 2000.
77. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sorensen HT, Schonheyder HC, and Lervang HH. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 34: 1080-1086, 2006.
78. Touyz RM, Yao G, Quinn MT, Pagano PJ, and Schiffrin EL. P47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 25: 512-518, 2005.
79. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, and Heller J. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46: 242-253, 2007.
80. Usatyuk PV, Romer LH, He D, Parinandi NL, Kleinberg ME, Zhan S, Jacobson JR, Dudek SM, Pendyala S, Garcia JG, and Natarajan V. Regulation of hyperoxia-induced NADPH oxidase activation in human lung endothelial cells by the actin cytoskeleton and cortactin. J Biol Chem 282: 23284-23295, 2007.
81. van 't Veer C and Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 272: 4367-4377, 1997.
82. Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier JP, Soria J, and Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22: 623-629, 2002.
83. Wagner AH, Kohler T, Ruckschloss U, Just I, and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69, 2000.
84. Waiczies S, Bendix I, Prozorovski T, Ratner M, Nazarenko I, Pfueller CF, Brandt AU, Herz J, Brocke S, Ullrich O, and Zipp F. Geranylgeranylation but not GTP loading determines Rho migratory function in T cells. J Immunol 179: 6024-6032, 2007.
85. Wang D, Hirase T, Inoue T, and Node K. Atorvastatin inhibits angiotensin II-induced T- type Ca2+ channel expression in endothelial cells. Biochem Biophys Res Commun 347: 394-400, 2006.
86. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, and Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation 99: 2027-2033, 1999.
87. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, and Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59: 646-654, 2001.
88. Zhan Y, He D, Newburger PE, and Zhou GW. P47(phox) px domain of NADPH oxidase targets cell membrane via moesin-mediated association with the actin cytoskeleton. J Cell Biochem 92: 795-809, 2004.
89. Zhang FL and Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269, 1996.
90. Ziegler T, Silacci P, Harrison VJ, and Hayoz D. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension 32: 351-355, 1998.